Cargando…

Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies

Digestive tumours, a common kind of malignancy worldwide, have recently led to the most tumour-related deaths. Angiogenesis, the process of forming novel blood vessels from pre-existing vessels, is involved in various physiological and pathological processes in the body. Many studies suggest that ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhengyang, Deng, Wei, Zhang, Xiao, An, Yongbo, Liu, Yishan, Yao, Hongwei, Zhang, Zhongtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784389/
https://www.ncbi.nlm.nih.gov/pubmed/35083147
http://dx.doi.org/10.3389/fonc.2021.789330
_version_ 1784638726494748672
author Yang, Zhengyang
Deng, Wei
Zhang, Xiao
An, Yongbo
Liu, Yishan
Yao, Hongwei
Zhang, Zhongtao
author_facet Yang, Zhengyang
Deng, Wei
Zhang, Xiao
An, Yongbo
Liu, Yishan
Yao, Hongwei
Zhang, Zhongtao
author_sort Yang, Zhengyang
collection PubMed
description Digestive tumours, a common kind of malignancy worldwide, have recently led to the most tumour-related deaths. Angiogenesis, the process of forming novel blood vessels from pre-existing vessels, is involved in various physiological and pathological processes in the body. Many studies suggest that abnormal angiogenesis plays an important role in the growth, progression, and metastasis of digestive tumours. Therefore, anti-angiogenic therapy is considered a promising target for improving therapeutic efficacy. Traditional strategies such as bevacizumab and regorafenib can target and block the activity of proangiogenic factors to treat digestive tumours. However, due to resistance and some limitations, such as poor pharmacokinetics, their efficacy is not always satisfactory. In recent years, nanotechnology-based anti-angiogenic therapies have emerged as a new way to treat digestive tumours. Compared with commonly used drugs, nanoparticles show great potential in tumour targeted delivery, controlled drug release, prolonged cycle time, and increased drug bioavailability. Therefore, anti-angiogenic nanoparticles may be an effective complementary therapy to treat digestive tumours. In this review, we outline the different mechanisms of angiogenesis, the effects of nanoparticles on angiogenesis, and their biomedical applications in various kinds of digestive tumours. In addition, the opportunities and challenges are briefly discussed.
format Online
Article
Text
id pubmed-8784389
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87843892022-01-25 Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies Yang, Zhengyang Deng, Wei Zhang, Xiao An, Yongbo Liu, Yishan Yao, Hongwei Zhang, Zhongtao Front Oncol Oncology Digestive tumours, a common kind of malignancy worldwide, have recently led to the most tumour-related deaths. Angiogenesis, the process of forming novel blood vessels from pre-existing vessels, is involved in various physiological and pathological processes in the body. Many studies suggest that abnormal angiogenesis plays an important role in the growth, progression, and metastasis of digestive tumours. Therefore, anti-angiogenic therapy is considered a promising target for improving therapeutic efficacy. Traditional strategies such as bevacizumab and regorafenib can target and block the activity of proangiogenic factors to treat digestive tumours. However, due to resistance and some limitations, such as poor pharmacokinetics, their efficacy is not always satisfactory. In recent years, nanotechnology-based anti-angiogenic therapies have emerged as a new way to treat digestive tumours. Compared with commonly used drugs, nanoparticles show great potential in tumour targeted delivery, controlled drug release, prolonged cycle time, and increased drug bioavailability. Therefore, anti-angiogenic nanoparticles may be an effective complementary therapy to treat digestive tumours. In this review, we outline the different mechanisms of angiogenesis, the effects of nanoparticles on angiogenesis, and their biomedical applications in various kinds of digestive tumours. In addition, the opportunities and challenges are briefly discussed. Frontiers Media S.A. 2022-01-10 /pmc/articles/PMC8784389/ /pubmed/35083147 http://dx.doi.org/10.3389/fonc.2021.789330 Text en Copyright © 2022 Yang, Deng, Zhang, An, Liu, Yao and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yang, Zhengyang
Deng, Wei
Zhang, Xiao
An, Yongbo
Liu, Yishan
Yao, Hongwei
Zhang, Zhongtao
Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies
title Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies
title_full Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies
title_fullStr Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies
title_full_unstemmed Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies
title_short Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies
title_sort opportunities and challenges of nanoparticles in digestive tumours as anti-angiogenic therapies
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784389/
https://www.ncbi.nlm.nih.gov/pubmed/35083147
http://dx.doi.org/10.3389/fonc.2021.789330
work_keys_str_mv AT yangzhengyang opportunitiesandchallengesofnanoparticlesindigestivetumoursasantiangiogenictherapies
AT dengwei opportunitiesandchallengesofnanoparticlesindigestivetumoursasantiangiogenictherapies
AT zhangxiao opportunitiesandchallengesofnanoparticlesindigestivetumoursasantiangiogenictherapies
AT anyongbo opportunitiesandchallengesofnanoparticlesindigestivetumoursasantiangiogenictherapies
AT liuyishan opportunitiesandchallengesofnanoparticlesindigestivetumoursasantiangiogenictherapies
AT yaohongwei opportunitiesandchallengesofnanoparticlesindigestivetumoursasantiangiogenictherapies
AT zhangzhongtao opportunitiesandchallengesofnanoparticlesindigestivetumoursasantiangiogenictherapies